WallStreetZenWallStreetZen

NASDAQ: AQST
Aquestive Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AQST

Based on 3 analysts offering 12 month price targets for Aquestive Therapeutics Inc

Min Forecast
$8.00+87.79%
Avg Forecast
$9.33+119.08%
Max Forecast
$12.00+181.69%

Should I buy or sell AQST stock?

Based on 3 analysts offering ratings for Aquestive Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AQST's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AQST as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AQST stock forecasts and price targets.

AQST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-07Find Out Why
lockedlocked$00.00+00.00%2025-10-09
lockedlocked$00.00+00.00%2025-09-08

1 of 1

Forecast return on equity

Is AQST forecast to generate an efficient return?

Company
-77.66%
Industry
59.24%
Market
180.15%
AQST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AQST forecast to generate an efficient return on assets?

Company
16.3%
Industry
19.26%
AQST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AQST earnings per share forecast

What is AQST's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.41
Avg 3 year Forecast
-$0.02

AQST revenue forecast

What is AQST's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$50.9M+14.23%
Avg 2 year Forecast
$80.6M+80.9%
Avg 3 year Forecast
$175.7M+294.34%
AQST's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AQST revenue growth forecast

How is AQST forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
54.43%
Industry
7.98%
Market
13.47%
AQST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AQST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AQST vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AQST$4.26$9.33+119.08%Strong Buy
KMDA$9.03$13.00+43.96%Buy
ETON$17.24$33.50+94.37%Buy
IRWD$3.62$7.67+111.80%Buy
SIGA$6.24N/AN/A
View Top Pharmaceutical Stocks

Aquestive Therapeutics Stock Forecast FAQ

Is Aquestive Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AQST) stock is to Strong Buy AQST stock.

Out of 3 analysts, 1 (33.33%) are recommending AQST as a Strong Buy, 2 (66.67%) are recommending AQST as a Buy, 0 (0%) are recommending AQST as a Hold, 0 (0%) are recommending AQST as a Sell, and 0 (0%) are recommending AQST as a Strong Sell.

If you're new to stock investing, here's how to buy Aquestive Therapeutics stock.

What is AQST's earnings growth forecast for 2026-2028?

(NASDAQ: AQST) Aquestive Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 13.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.32%.

Aquestive Therapeutics's earnings in 2026 is -$83,784,000.On average, 11 Wall Street analysts forecast AQST's earnings for 2026 to be -$71,493,990, with the lowest AQST earnings forecast at -$95,683,318, and the highest AQST earnings forecast at -$33,318,298. On average, 7 Wall Street analysts forecast AQST's earnings for 2027 to be -$50,624,286, with the lowest AQST earnings forecast at -$69,370,406, and the highest AQST earnings forecast at -$11,533,257.

In 2028, AQST is forecast to generate -$2,489,719 in earnings, with the lowest earnings forecast at -$3,588,124 and the highest earnings forecast at -$1,281,473.

What is AQST's revenue growth forecast for 2026-2028?

(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 54.43% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Aquestive Therapeutics's revenue in 2026 is $44,545,000.On average, 11 Wall Street analysts forecast AQST's revenue for 2026 to be $6,210,262,318, with the lowest AQST revenue forecast at $4,544,957,625, and the highest AQST revenue forecast at $9,503,159,785. On average, 7 Wall Street analysts forecast AQST's revenue for 2027 to be $9,834,634,139, with the lowest AQST revenue forecast at $6,111,771,964, and the highest AQST revenue forecast at $16,613,992,520.

In 2028, AQST is forecast to generate $21,438,433,307 in revenue, with the lowest revenue forecast at $13,694,674,948 and the highest revenue forecast at $28,320,553,620.

What is AQST's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AQST) forecast ROA is 16.3%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.26%.

What is AQST's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AQST price target, the average AQST price target is $9.33, with the highest AQST stock price forecast at $12.00 and the lowest AQST stock price forecast at $8.00.

On average, Wall Street analysts predict that Aquestive Therapeutics's share price could reach $9.33 by Nov 7, 2026. The average Aquestive Therapeutics stock price prediction forecasts a potential upside of 119.08% from the current AQST share price of $4.26.

What is AQST's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AQST) Aquestive Therapeutics's current Earnings Per Share (EPS) is -$0.78. On average, analysts forecast that AQST's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.78, and the highest EPS forecast at -$0.27. On average, analysts forecast that AQST's EPS will be -$0.41 for 2027, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.09. In 2028, AQST's EPS is forecast to hit -$0.02 (min: -$0.03, max: -$0.01).

What is AQST's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AQST) forecast ROE is -77.66%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.